Fresenius Medical reports Q4 EPS ex-items EUR1.44 vs. EUR0.91 last year

Reports Q4 revenue EUR5.07B vs. EUR5.08B last year. “Fresenius Medical (FMS) Care closed a milestone year marked by outstanding profitability gains. Over the past three years, we built a stronger and more resilient company, meeting all key financial and strategic aspects of the mid-term outlook that we had set for 2025. In 2025, we delivered revenue and operating income growth at the upper end of our outlook, overcoming a difficult market environment,” said CEO Helen Giza. “Our operating income margin of 11.3% is well within the mid-term margin target band we established three years ago for 2025. The Group’s step-up in profitability was the result of solid business growth, accelerated FME25+ efficiency gains, higher-than-expected benefits from TDAPA regulation and favorable reimbursement developments, with all segments making meaningful contributions. Looking ahead to 2026, we are set to build on the remarkable transformation of recent years and advance the execution of our FME Reignite strategy. For our patients, we are excited to expand access to high-volume hemodiafiltration in the U.S. with the large-scale rollout of our innovative 5008X CAREsystem. We expect to grow operating income by three to seven percent CAGR out to 2028 and to increase returns for our shareholders.”